Alembic Pharmaceuticals Ltd

Alembic Pharma | 533573

Market Closed

₹821.75

+₹7.65 (+0.94%)

As on 24/08/26, 3:49 AM

Market Cap16,152.57 CR

Current Price₹821.75

High / Low₹998 / 635.8

PE Ratio19.28

Book Value₹288.72

Dividend Yield1.81%

ROCE11.24%

ROE12.90%

Face Value₹2.00

Current Vol.35,565

Average Vol.---

ISININE901L01018

PB Ratio2.29

Debt to Equity0.25

Net Profit Margin9.13

Operating Margin15.06

APLLTD - Share Price Chart

+₹0.00 (+0.00%)6M

Stock Performance

₹814.1₹815

₹821.75

Previous CloseToday's Open

₹635.8₹998

₹821.75

52W Low52W High

₹815Today's Open

₹814.1Previous Close

35,565Volume

₹635.852W Low

₹99852W High

Ratios

No data available

About Company

Alembic Pharmaceuticals Limited is a leading research-driven, integrated pharmaceutical enterprise specialising in the development and manufacturing of generic formulations across diverse therapeutic areas, including cardiology, anti-infective, gynaecology, ophthalmology, oncology and chronic therapies
Alembic Pharmaceuticals Limited was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Limited
The company is engaged in pharmaceuticals business
As per the Scheme of Arrangement, the 'Pharmaceutical Undertaking' of Alembic Limited got demerged and transferred to the Company with effect from April 1, 2010
In April 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement
The shareholding of Alembic Ltd in the company reduced from 100% to 29
Thus, the company became an associate of Alembic Ltd
In September 2011, the equity shares of the company were listed on the Bombay Stock Exchange and National Stock Exchange
During 2012, Alembic and Breckenridge Announced Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiq)
The company enters into a product development and license agreement with Accu-Break Pharmaceuticals, Inc, USA

Ethics: Alembic Pharmaceuticals Ltd is flagged for

Animal Cruelty

The company engages directly in some form of animal cruelty through its business.

Adequate

The company demonstrates adequate ESG practices with room for improvement.

Research Calls

Explore all active research calls & maximize your profits

To access, login or signup with ArihantPlus

Technical Indicators

RSI51.38

SMA 20820.88

SMA 50809.51

SMA 100776.12

SMA 200794.35

SMA 10827.47

MACD_12_26_Days3.53

EMA10Day822.90

EMA20Day821.58

EMA50Day807.88

MACD_12_26_9_Days-2.05

EMA100Day795.70

EMA200Day812.50

Pivot Points

Volume Analysis

Delivery

Total Volume

Growth Rate

Revenue Growth10.08%

ROE12.35%

EBITDA Margin15.06%

All figures in ₹ Crores

Indicators	2026	2025	2024	2023	2022
Revenue	7,344.90	6,672.08	6,228.63	5,652.62	5,305.79
Interest	93.63	78.77	56.19	50.17	17.73
Expenses	6,226.44	5,663.85	5,296.24	4,975.17	4,431.63
Financing Profit	1,173.12	1,051.66	960.69	680.19	929.90
Financing Margin %	16%	16%	15%	12%	18%
Other Income	54.66	43.43	28.30	2.74	55.74
Depreciation	318.55	278.58	272.67	275.43	286.78
Profit before tax	693.95	707.18	631.83	354.59	625.39
Tax %	3%	18%	3%	4%	17%
Net Profit	670.83	582.01	615.82	341.99	520.94
EPS in Rs	34.33	29.68	31.33	17.40	26.50

Show % Change

ShareHolding

📊

No Information Available

No shareholding data available at this time.

Deal	Date	Type	Quantity	Price	Traded %
ISHARES CORE EMERGING MARKETS MAURITIUS CO	03 Oct ‘22	Sell	1,78,908	₹604.65	167.92%
ISHARES CORE MSCI EMERGING MARKETS ETF	03 Oct ‘22	Purchase	1,78,908	₹604.65	167.92%
ISHARES INDIA SC MAURITIUS COMPANY	03 Oct ‘22	Sell	25,151	₹604.65	23.61%
ISHARES MSCI INDIA SMALL-CAP ETF	03 Oct ‘22	Purchase	25,151	₹604.65	23.61%

News

📊

No Information Available

No news available for this company.

Record Date

Corporate Action

Information

Announcement Day

05 Aug 2026

AGM

10 Jul 2026

29 Jul 2026

Final Dividend (₹12)

Recommended a dividend of Rs. 12/- per Equity Share having face value of Rs.2each (600%) for the financial year ended 31st March, 2026.

15 May 2026

05 Aug 2025

AGM

11 Jun 2025

29 Jul 2025

Final Dividend (₹11)

Please find attached herewith the Financial Results for the quarter and Financial Year ended 31st March, 2025 Recommended a dividend of Rs. 11/- (550%) per Equity Share having face value of Rs. 2/- each, subject to approval of the Shareholders at the ensuing Annual General Meeting. This is to inform that the Company has fixed the Record Date of 29th July, 2025 for determining the entitlement of Members of the Company to receive dividend for the Financial Year ended 31st March, 2025. (As Per BSE Announcement Dated on :11.06.2025)

06 May 2025

22 Jul 2024

AGM

21 Jun 2024

15 Jul 2024

Final Dividend (₹11)

The exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today Approved the Audited Financial Results for the quarter and financial year ended 31st March, 2024, and Recommended a dividend of Rs. 11/- (550%) per Equity Share

09 May 2024

04 Aug 2023

AGM

05 Jun 2023

28 Jul 2023

Final Dividend (₹8)

The exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter alia Approved the Audited Financial Results for the quarter and financial year ended 31st March, 2023. and Recommended a dividend of Rs. 8/- (400%) per Equity Share. The Company has fixed Friday, 28th July, 2023 as the record date for determining the entitlement of Members to final dividend for the financial year ended 31st March, 2023. (As Per BSE Announcement Dated on 21.06.2023)

05 May 2023

11 Nov 2022

AGM

19 Sept 2022

18 Aug 2022

Interim Dividend (₹10)

Alembic Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 02, 2022, inter alia, has recommended a dividend of Rs. 10/- (500%) per Equity Share having face value of Rs. 2/- each, subject to approval of the Shareholders at the ensuing Annual General Meeting. With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter alia approved: 1) Unaudited Financial Results for the quarter ended 30th June, 2022. 2) Re-classification of the dividend of Rs. 10/- (500%) per equity share for the financial year 2021-22, recommended by them at their meeting held on 2nd May, 2022, into interim dividend for the financial year 2021-22. Please note that the said interim dividend will be paid to those shareholders whose names appear on the Register of Members as on the Record Date fixed for the purpose i.e. Thursday, 18th August, 2022. No further final dividend for the financial year 2021-22 shall be declared. The time of commencement of the Board Meeting was 12:30 p.m. and the time of conclusion was 3:30 p.m. We request you to kindly take the same on record. (As Per BSE Announcement Dated on 04.08.2022)

02 May 2022

Peers

LTP(₹)	Market Cap(₹ Cr.)	P/E Ratio(Ratio)	P/B Ratio(Ratio)	Cash Earnings(Ratio)	Debt to Equity(Ratio)	Net Profit Ratio(%)
821	16,128	22	3	15	0	9.13%
1,901	4,56,090	36	5	29	0	19.78%
8,550	2,26,976	76	14	66	0	24.32%
4,881	1,85,639	83	22	50	1	11.09%
1,426	1,15,216	32	3	24	0	9.92%
1,120	1,11,720	23	4	17	0	9.82%
2,193	1,00,271	17	4	13	0	19.16%
1,175	98,074	30	3	18	0	12.34%
1,815	98,048	90	18	62	1	13.06%
2,372	97,963	46	6	32	0	13.57%

Showing 10 of 138 Results

#IndiaInvests

Trusted by 2.5 lac + Indians for their wealth-building needs

Invest in stocks with ease

Open your account in just 5 minutes*

By proceeding, you agree to all T&C *

Top Gainers

Top Losers

BSEBSE Ltd
₹3,241-50.1 (-1.52%)

Group Stocks

Adani Stocks

Tata Group Stocks

Frequently Asked Questions

What is Share Price of Alembic Pharmaceuticals Ltd?

The current share price of Alembic Pharmaceuticals Ltd (Alembic Pharma) is ₹821.75. This price reflects the latest market valuation and is updated in real-time during trading hours.

What is the P/E Ratio of Alembic Pharmaceuticals Ltd?

The Price-to-Earnings (P/E) ratio of Alembic Pharmaceuticals Ltd is 821.75. This indicates how much investors are willing to pay per rupee of earnings, helping assess if the stock is overvalued or undervalued.

What is the 52-week high and low of Alembic Pharmaceuticals Ltd?

Alembic Pharmaceuticals Ltd has a 52-week high of ₹998.00 and a 52-week low of ₹635.80. This range shows the stock's price volatility over the past year.

What is the Dividend Yield of Alembic Pharmaceuticals Ltd?

Alembic Pharmaceuticals Ltd offers a dividend yield of 1.46%. This represents the annual dividend payment as a percentage of the current stock price, indicating the income return for investors.

What is the EPS of Alembic Pharmaceuticals Ltd?

The Earnings Per Share (EPS) of Alembic Pharmaceuticals Ltd is ₹37.96. EPS indicates the company's profitability on a per-share basis and is a key metric for evaluating financial performance.

What is the ROE of Alembic Pharmaceuticals Ltd?

Alembic Pharmaceuticals Ltd has a Return on Equity (ROE) of 12.90%. ROE measures how effectively the company uses shareholders' equity to generate profits, with higher values generally indicating better performance.

Disclaimer:

Please note that the above list and information is for research purposes only and are not recommendations. Do your own due diligence or consult an investment advisor before investing. The above data is dynamic in nature and subject to real-time changes and is derived from CMOTS.

Ready to invest smarter?
Download the app today.

GET IT ON

Google Play

4.5

DOWNLOAD ON THE

App Store

4.2

Discover our app's power in seconds. Play Video